Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.5820
+0.0682 (13.27%)
At close: Jun 25, 2025, 4:00 PM
0.5836
+0.0016 (0.27%)
After-hours: Jun 25, 2025, 7:58 PM EDT
Sangamo Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Sangamo Therapeutics stock have a consensus rating of "Buy" and an average price target of $4.5, which forecasts a 673.2% increase in the stock price over the next year. The lowest target is $2 and the highest is $10.
Price Target: $4.5 (+673.2%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sangamo Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,618.21% | Jun 24, 2025 |
| Barclays | Barclays | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +759.11% | May 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,618.21% | Apr 7, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $2 | Hold | Reiterates | $2 | +243.64% | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,618.21% | Jan 27, 2025 |
Financial Forecast
Revenue This Year
54.85M
from 57.80M
Decreased by -5.11%
Revenue Next Year
54.34M
from 54.85M
Decreased by -0.93%
EPS This Year
-0.37
from -0.49
EPS Next Year
-0.36
from -0.37
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 111.7M | 119.7M | 274.7M | ||
| Avg | 54.8M | 54.3M | 105.6M | ||
| Low | 20.4M | 9.7M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 93.3% | 118.2% | 405.5% | ||
| Avg | -5.1% | -0.9% | 94.3% | ||
| Low | -64.7% | -82.3% | -63.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.18 | -0.18 | 0.22 | ||
| Avg | -0.37 | -0.36 | -0.23 | ||
| Low | -0.53 | -0.54 | -0.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.